NUTM2A and neuroblastoma: Post‐knockdown, the CCK‐8 assay indicated a significant reduction in the IC50 values of cisplatin in NUTM2A‐AS1 silenced SH‐SY5Y‐R and SK‐N‐SH‐R cells compared to the original resistant models (Figure 1E,F), reinforcing the hypothesis that NUTM2A‐AS1 functions pivotally in cisplatin‐resistant NB.